ICON Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de ICON de 14.9% y 6.8% por año respectivamente. Se prevé que el BPA crezca en un 13.7% al año. Se espera que la rentabilidad financiera sea de 13% en 3 años.

Información clave

14.1%

Tasa de crecimiento de los beneficios

14.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	16.6%
Tasa de crecimiento de los ingresos	6.7%
Rentabilidad financiera futura	13.2%
Cobertura de analistas	Good
Última actualización	29 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 28

Recent updates

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 28

What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?

Apr 21

ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price

Apr 05

ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump

Mar 05

Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth

Aug 11

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?

Aug 01

Icon Q2 2022 Earnings Preview

Jul 26

ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet

May 11

ICON Public Limited Company (NASDAQ:ICLR) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 20

Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?

Feb 16

We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt

Jan 26

Estimating The Intrinsic Value Of ICON Public Limited Company (NASDAQ:ICLR)

Jan 05

Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?

Oct 31

ICON (NASDAQ:ICLR) Has A Rock Solid Balance Sheet

Oct 16

Estimating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Oct 01

ICON PLC: An Easy Stock To Choose For Diversified Exposure To Healthcare And Clinical Research

Aug 26

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ICLR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	9,943	1,139	1,528	1,745	9
12/31/2025	9,282	1,000	1,420	1,583	13
12/31/2024	8,641	820	1,183	1,293	13
3/31/2024	8,232	683	1,172	1,313	N/A
12/31/2023	8,120	612	1,020	1,161	N/A
9/30/2023	8,016	513	516	661	N/A
6/30/2023	7,903	510	381	534	N/A
3/31/2023	7,818	510	363	512	N/A
12/31/2022	7,741	505	421	563	N/A
9/30/2022	7,665	464	780	913	N/A
6/30/2022	7,588	210	878	998	N/A
3/31/2022	6,524	168	839	944	N/A
12/31/2021	5,481	153	735	829	N/A
9/30/2021	4,356	178	676	735	N/A
6/30/2021	3,191	364	506	548	N/A
3/31/2021	2,940	338	499	537	N/A
12/31/2020	2,797	328	527	568	N/A
9/30/2020	2,762	322	460	507	N/A
6/30/2020	2,771	324	502	556	N/A
3/31/2020	2,846	368	406	461	N/A
12/31/2019	2,806	369	374	413	N/A
9/30/2019	2,759	362	287	339	N/A
6/30/2019	2,704	353	257	306	N/A
3/31/2019	2,651	333	276	323	N/A
12/31/2018	2,596	323	220	269	N/A
9/30/2018	2,372	306	264	314	N/A
6/30/2018	2,157	295	248	294	N/A
3/31/2018	1,947	288	220	264	N/A
12/31/2017	1,758	281	N/A	383	N/A
9/30/2017	1,738	285	N/A	407	N/A
6/30/2017	1,718	274	N/A	350	N/A
3/31/2017	1,698	271	N/A	359	N/A
12/31/2016	1,666	262	N/A	259	N/A
9/30/2016	1,635	251	N/A	245	N/A
6/30/2016	1,609	249	N/A	267	N/A
3/31/2016	1,587	247	N/A	277	N/A
12/31/2015	1,575	240	N/A	279	N/A
9/30/2015	1,562	221	N/A	239	N/A
6/30/2015	1,555	210	N/A	275	N/A
3/31/2015	1,542	192	N/A	192	N/A
12/31/2014	1,503	172	N/A	169	N/A
9/30/2014	1,458	161	N/A	192	N/A
6/30/2014	1,411	138	N/A	125	N/A
3/31/2014	1,369	120	N/A	191	N/A
12/31/2013	1,336	103	N/A	221	N/A
9/30/2013	1,291	90	N/A	136	N/A
6/30/2013	1,237	80	N/A	121	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (14.9% al año) de ICLR es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (14.1% al año) de ICLR crezcan menos que el mercado US (14.1% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de ICLR crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (6.8% al año) de ICLR crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.8% al año) de ICLR crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ICLR sea baja dentro de 3 años (13%).

ICON Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Price target increased by 13% to US$349

ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024

ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024

Price target increased by 7.6% to US$279

Icon Public Limited Company Reaffirms Revenue Guidance for Full Year 2022 and Provides Revenue Guidance for Full Year 2023

Recent updates

ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next

Now 20% undervalued

First quarter 2024 earnings: EPS exceeds analyst expectations

What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?

ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price

Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024

Now 20% undervalued

ICON Public Limited Company to Report Q1, 2024 Results on Apr 24, 2024

Now 20% undervalued

ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump

Price target increased by 13% to US$349

Full year 2023 earnings: EPS exceeds analyst expectations

ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024

With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?

ICON Public Limited Company to Report Q4, 2023 Results on Feb 21, 2024

These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024

Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E

Board Member notifies of intention to sell stock

A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Chief Financial Officer notifies of intention to sell stock

With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

ICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions.

Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

ICON Public Limited Company to Report Q3, 2023 Results on Oct 25, 2023

ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation Solution

CEO & Director notifies of intention to sell stock

ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical Trial

Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

Board Member notifies of intention to sell stock

Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?

CEO & Director notifies of intention to sell stock

Price target increased by 7.6% to US$279

Second quarter 2023 earnings: EPS misses analyst expectations

Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?

ICON Public Limited Company to Report Q2, 2023 Results on Jul 26, 2023

ICON Public Limited Company, Annual General Meeting, Jul 25, 2023

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Key Executive notifies of intention to sell stock

Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)

First quarter 2023 earnings: EPS misses analyst expectations

Now 20% undervalued after recent price drop

Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?

Is ICON (NASDAQ:ICLR) Using Too Much Debt?

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?

ICON Public Limited Company to Report Q4, 2022 Results on Feb 22, 2023

Icon Public Limited Company Reaffirms Revenue Guidance for Full Year 2022 and Provides Revenue Guidance for Full Year 2023

Insufficient new directors

Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching

Chief Information Officer notifies of intention to sell stock

These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well

Chief Financial Officer notifies of intention to sell stock

Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?

Third quarter 2022 earnings: EPS exceeds analyst expectations

Icon selected by BARDA to conduct anthrax vaccine clinical trial

ICON Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?

ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly

Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth

Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?

Second quarter 2022 earnings: EPS misses analyst expectations

Icon Public Limited Company Revises Earnings Guidance for the Year 2022

Icon Q2 2022 Earnings Preview

ICON Public Limited Company to Report Q2, 2022 Results on Jul 27, 2022